Filing Flows › AtriCure (ATRC) › Guidance & outlook
AtriCure (ATRC) guidance and outlook
AtriCure (ATRC) raised its guidance on Nov 3, 2026: Revenue $606M–$610M for FY2026; EBITDA $91.0M–$94.0M for FY2026; EPS $0.21–$0.27 for FY2026; EPS $0.40–$0.46 for FY2026. AtriCure's 10-Q filed Nov 4, 2026 makes 6 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $606M–$610M | raised |
| EBITDA | FY2026 | $91.0M–$94.0M | raised |
| EPS | FY2026 | $0.21–$0.27 | raised |
| EPS | FY2026 | $0.40–$0.46 | raised |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- We anticipate that substantially all of our revenue for the foreseeable future will relate to products we currently sell or are in the process of developing.
- We expect to commercially launch the product before the end of 2026.
- We expect to complete site initiation and enrollment during the fourth quarter of 2026.
- Research and development expenses increased $9,224, or 40.3%, primarily driven by a $4,500 milestone payment for acquired IPR&D made in the third quarter of 2026; $3,038 increase in clinical activity costs, largely attributable to BoxX-NoAF trial enrollment; and $1,579 incremental investment in our product pipeline through new product development projects.
- Research and development expenses increased $8,049, or 10.8%, driven by $2,451 higher clinical activity costs from BoxX-NoAF enrollment in 2026 offset by the close of LeAAPS enrollment during 2025; a $2,382 increased investment in our product pipeline through new product development projects; $1,474 increased regulatory filing and submission costs, and $1,090 higher personnel costs, including share-based…
- We continue to evaluate additional measures to maintain financial flexibility, and we will continue to closely monitor macroeconomic conditions including, but not limited to, inflationary pressures, changes in interest rates and fluctuations in currency exchange rates that may impact our liquidity and access to capital resources.
AtriCure's latest quarter
AtriCure, Q3 2026: revenue $154M (+15% year over year), operating margin 2.8%, net earnings $4.1M, operating cash flow $30.3M. The chart follows the revenue to costs, profit and cash.
Questions
Did AtriCure raise or lower its guidance?
AtriCure (ATRC) raised its guidance on Nov 3, 2026: Revenue $606M–$610M for FY2026; EBITDA $91.0M–$94.0M for FY2026; EPS $0.21–$0.27 for FY2026; EPS $0.40–$0.46 for FY2026.
What does AtriCure expect?
We anticipate that substantially all of our revenue for the foreseeable future will relate to products we currently sell or are in the process of developing. We expect to commercially launch the product before the end of 2026. We expect to complete site initiation and enrollment during the fourth quarter of 2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.